Most Read This Week
- Ten Practice Changes That I Will Make After Attending ASCO 2022
- Prevalence of CRC Screening Remains Low in Those Aged 50 to 54
- Overall Survival With First-Line Palbociclib Plus Letrozole vs Placebo Plus Letrozole in Women With ER+/HER2− Advanced Breast Cancer
- Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Patients With HER2+ Unresectable and/or Metastatic Breast Cancer
- SurVaxM for Newly Diagnosed Glioblastoma
Recently Updated
- Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
- Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low- or Intermediate-Risk Localized Prostate Cancer
- E-Noses Promising for Diagnosing Cancer from Exhaled Breath
- Prevalence of CRC Screening Remains Low in Those Aged 50 to 54
- Long-Term Survival in Patients With Anaplastic Oligodendroglioma Who Received Radiotherapy Plus PCV Chemotherapy